Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azd7648 + pegylated liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**AZD7648 + pegylated liposomal doxorubicin** is a combination therapy consisting of AZD7648, an oral small molecule inhibitor of DNA-dependent protein kinase (DNA-PK), and pegylated liposomal doxorubicin (PLD), an encapsulated formulation of doxorubicin designed to reduce toxicity. AZD7648 selectively inhibits DNA-PK, impairing double-strand break repair via the nonhomologous end joining (NHEJ) pathway and potentiating the cytotoxic effects of DNA-damaging agents such as PLD. The combination is under investigation as a treatment for advanced or metastatic solid tumors and ovarian cancer, aiming to enhance tumor cell death by blocking DNA repair while reducing systemic toxicity through pegylation of doxorubicin[2][4][7].
- Other names
- PLDpegylated liposomal doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)DNADNA-PK (DNA-dependent protein kinase)
Beyond the preview
Go deeper on azd7648 + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azd7648 + pegylated liposomal doxorubicin.